Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 Form 6 - K Report of Foreign Private Issuer Pursuant to Rule 13a - 16 or 15d - 16 under the Securities Exchange Act of 1934 December 2021 Commission file number : 001-36288 Akari Therapeutics , Plc ( Translation of registrant's name into English ) 75/76 Wimpole Street London W1G 9RT United Kingdom ( Address of principal executive offices ) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20 - F or Form 40 - F . Form 20 - F x Form 40 - F Indicate by check mark if the registrant is submitting the Form 6 - K in paper as permitted by Regulations S - T Rule 101 ( b ) ( 1 ) : ¨ * Indicate by check mark if the registrant is submitting the Form 6 - K in paper as permitted by Regulations S - T Rule 101 ( b ) ( 7 ) : ¨ CONTENTS On December 3 , 2021 , Akari Therapeutics , Plc ( the “ Company ” ) issued unaudited interim condensed consolidated financial statements as of September 30 , 2021 , prepared in accordance with generally accepted accounting principles in the United States , together with the Company's Management Discussion and Analysis of Financial Condition and Results of Operations for the same period . Attached hereto and incorporated by reference herein are the following exhibits : 99.1 99.2 Unaudited Interim Condensed Consolidated Financial Statements as of September 30 , 2021 Management Discussion and Analysis of Financial Condition and Results of Operations as of September 30 , 2021 In addition , on December 3 , 2021 , the Company issued a press release announcing its third quarter 2021 financial results and recent clinical progress highlights . A copy of the press release is attached hereto as Exhibit 99.3 , and incorporated herein by reference .